Animal study · Supplements / medicine · 3 Nov 2026
In aged rats, two weeks of the experimental drug cinaciguat cut circulating amyloid-beta about in half and brought LDL down to youthful levels
Source: ScienceDaily
What the research found
USC researchers reported in the Journal of Biological Chemistry that two weeks of cinaciguat, an experimental drug, restored pores in aging liver sinusoidal endothelial cells in older rats. Circulating amyloid-beta fell by about half, near the levels in young rats. LDL cholesterol also fell to youthful levels. The group describes a signal in which those lining cells release HB-EGF and neighboring hepatocytes take up more LDL and amyloid-beta. Laurie DeLeve said more translational work is required. The study did not show fewer brain plaques, and it did not count heart attacks. It is rat research, not a medicine for people, and not a substitute for prescribed care. DOI 10.1016/j.jbc.2026.113608. ScienceDaily dated its page 2 November 2026. The feed time falls on 3 November in Bangkok. Not medical advice.
Evidence level: Animal study. Results in animals or cells often don't carry over to people.
More supplements / medicine news
- In mice, the experimental drug KCL-286 reduced DNA breaks and brain inflammation in an Alzheimer's model
- In 104 people with a sudden retinal-artery blockage, papaverine use lined up with better functional vision in a retrospective comparison
- A Cell Metabolism letter questions whether a fasting GLP-1 level shows how many gut L-cells a person has
- In FDA reports, caffeine and stimulant supplement use was tied to cardiac arrest about 11 times more often, and 45 percent of those cardiovascular reports were ages 18 to 34
- In 52,330 women ages 45 to 59, starting contemporary prescription hormone therapy did not raise heart, stroke, clot, or death rates over 12 years